Cell Therapy Startup Funding 2025-2026

What are all the funding deals in the cell therapy market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play cell therapy companies between August 2025 and July 2026. We count as “pure-play” cell therapy companies those focused on living-cell medicinal products used as drugs, including CAR-T, engineered immune cells, allogeneic platforms, autologous therapies, regenerative cell therapies, and major late-stage cell-based medicines.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of the category, we cover the full opportunity in our Cell Therapy market report.

How active has fundraising been in the cell therapy market?

As of July 2026, fundraising in the cell therapy market has been active but selective. Over the past 12 months, companies raised 34 disclosed equity rounds and $2.05B combined, equal to 3.09 deals per month.

The cell therapy market had consistent deal formation across the period, but capital did not arrive evenly. The median month had 3 deals and $116.6M raised, while the average month had $186.6M.

January 2026 was the decisive funding month. It produced 5 deals and $655.0M, which means one month accounted for 31.9% of disclosed capital.

This makes monthly deal count a weak proxy for market strength. February 2026 had 4 deals but only $68.14M, showing how round size matters more than activity alone.

For a wider breakdown of company activity and financing patterns, see our cell therapy market report.

How concentrated has fundraising been in the cell therapy market?

As of July 2026, fundraising in the cell therapy market is concentrated, but not dependent on one winner. Over the past 12 months, the top 1 deal represented 12.2% of disclosed capital, while the top 10 deals captured 65.3%.

The top 3 deals reached 28.8% of total capital, and the top 5 reached 41.3%. That is a strong concentration signal, but it is not a single-outlier market.

The better interpretation is that capital clustered around a small group of validated companies. Orca Bio, Allogene Therapeutics, MEDIPOST, Century Therapeutics, CREATE Medicines, and Aspen Neuroscience each raised checks large enough to shape the overall market.

This matters because the headline $2.05B total can make the cell therapy market look broadly liquid. In reality, the strongest liquidity was reserved for companies with scale, late-stage proximity, or platform credibility.

How much of the cell therapy funding signal is driven by outliers?

As of July 2026, the cell therapy market funding signal is strongly influenced by large rounds. Over the past 12 months, 16 deals were $50M or larger, and 8 deals were above $100M.

Rounds above $50M represented 38.2% of all deals, but they drove most of the disclosed capital. Excluding rounds above $50M leaves only $542.5M, meaning 73.6% of capital was tied to larger checks.

The median round size was $47.0M, while the average round size was $60.4M. The average sits higher because large financings pull the total upward.

This is why average deal size should not be read as the typical company experience. The median is a better guide to what a visible, fundable company could raise in this period.

Is the cell therapy market broad with many targets, or narrow with few fundable companies?

As of July 2026, the cell therapy market is broader than a single-modality market but still narrow in who receives major capital. Over the past 12 months, 34 deals involved 33 unique companies, so repeat company activity was limited.

At the category level, the market is not only CAR-T. CAR T Therapies led with 13 deals, but Regenerative Cell Therapies added 8 deals, Allogeneic Cell Therapies added 5, and several other categories were visible.

At the dollar level, the market is much narrower. The top 10 deals captured 65.3% of disclosed capital, so a small group of companies drove most of the financing signal.

The cell therapy market should therefore be read as scientifically broad but financially selective. Many modalities can raise, but only a subset can command scale capital.

Is cell therapy mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the cell therapy market looks more like a late-stage scaling market than an early-stage formation market. Over the past 12 months, late-stage categories and growth financings captured the largest dollar share.

Growth Equity was the largest stage by capital, with $652.9M, or 31.8% of the total. Series C added $394.64M, and Series D+ added $298.0M.

Early-stage rounds were active but smaller. Seed, Series A, and Series B together raised $562.4M, equal to 27.4% of disclosed capital, while late-stage rounds raised $1.35B.

Series A tied Growth Equity for deal count with 8 rounds each, but Series A captured only 13.3% of dollars. That means company formation exists, but the largest checks went to companies with more maturity.

We cover the stage split and investor implications in more depth in our deeper analysis of the cell therapy market.

Which categories attract the most investor attention in cell therapy?

As of July 2026, CAR T Therapies attract the most investor attention in the cell therapy market. Over the past 12 months, CAR-T companies raised 13 deals and $643.0M.

CAR T Therapies represented 38.2% of all deals and 31.3% of disclosed capital. That makes CAR-T the broadest financing theme, but not the only important one.

Regenerative Cell Therapies were second by deal count, with 8 deals, while Allogeneic Cell Therapies were second by capital, with $510.9M. This shows different kinds of investor attention: broad experimentation versus larger conviction checks.

Late Stage Cell Therapies had only 2 deals but $390.0M. That confirms that investors rewarded companies closer to pivotal trials, commercial readiness, or product launch.

Which categories attract disproportionately large checks in the cell therapy market?

As of July 2026, Late Stage Cell Therapies attract the most disproportionately large checks in the cell therapy market. Over the past 12 months, they represented only 5.9% of deals but 19.0% of capital.

The capital-share-to-deal-share ratio for Late Stage Cell Therapies was 3.23, the highest in the dataset. That means each visible deal carried much more weight than the category’s deal count suggests.

Allogeneic Cell Therapies also attracted premium checks. The category had a ratio of 1.69, with $510.9M from only 5 deals, helped by Allogene Therapeutics, Century Therapeutics, Wugen, Tr1X, and Ernexa.

Regenerative Cell Therapies and Engineered Immune Cells had lower ratios, at 0.55 and 0.54. They were fundable, but investors wrote smaller average checks unless there was stronger late-stage or scalability evidence.

For more detail on category-level check sizes, see our market report covering cell therapy funding patterns.

Which geographies matter most for fundraising in the cell therapy market?

As of July 2026, North America matters most for fundraising in the cell therapy market. Over the past 12 months, North America produced 19 deals and $1.38B in disclosed capital.

North America captured 55.9% of deals and 67.3% of capital. Its average deal size was $72.7M, and its median round size was $50.0M.

Asia-Pacific was the second-largest region, with 11 deals and $570.64M. It represented 32.4% of deal count and 27.8% of capital, showing real depth across CAR-T and regenerative cell therapy companies.

Europe was smaller, with 4 deals and $100.6M. Its median deal size was $21.5M, which makes it a more selective specialist market in this period.

Is the cell therapy opportunity set broad or concentrated in one hub?

As of July 2026, the cell therapy opportunity set is concentrated in two major hubs rather than one. Over the past 12 months, North America and Asia-Pacific together held 88.3% of deals and 95.1% of disclosed capital.

North America was the larger capital hub, especially for late-stage and growth financings. The region was home to Orca Bio, Allogene Therapeutics, Century Therapeutics, Aspen Neuroscience, CREATE Medicines, and several other large rounds.

Asia-Pacific was also central to the cell therapy market. Its companies raised across allogeneic, CAR-T, regenerative, and late-stage cell therapy categories, making the region more than a marginal contributor.

Europe appeared in the dataset, but it did not set the overall capital tempo. Latin America, the Middle East, and Africa had no qualifying disclosed equity rounds in the sample.

For more geographic context, explore our full market deck on cell therapy.

Is cell therapy a market of small experiments or scaled financings?

As of July 2026, cell therapy is a market of scaled financings, not just small experiments. Over the past 12 months, 16 of 34 disclosed deals were at or above $50M.

The size distribution shows a strong middle and upper tier. There was 1 deal below $5M, 7 deals from $5M to below $20M, 10 deals from $20M to below $50M, and 16 deals at $50M or more.

Eight deals cleared $100M, equal to 23.5% of all disclosed rounds. That is a meaningful signal in a capital-intensive therapeutic market where clinical trials and manufacturing can require large budgets.

The $50M threshold is important. Below it, companies are usually funding proof-building work; above it, they are often financing major clinical, manufacturing, corporate, or commercialization milestones.

Who are the investors that appear the most in cell therapy fundraising?

As of July 2026, repeat investors in the cell therapy market were limited. Over the past 12 months, only a few named investors appeared in more than one disclosed deal.

Qiming Venture Partners appeared in two Oricell Therapeutics rounds. Beijing Medical and Health Care Industry Investment Fund also appeared in two Oricell financings.

RA Capital Management appeared in both Azalea Therapeutics and Century Therapeutics. That makes it one of the few named investors in the dataset with exposure to more than one company.

There is an important caveat. Investor disclosure was incomplete in several announcements, and public sources usually do not reveal individual check sizes. So repeat-investor analysis should be read as participation frequency, not dollars committed.

If you want to compare investors and funding rounds across the full dataset, see our cell therapy market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.